Ascendis Pharma AS (ASND)

NASDAQ
Currency in USD
175.37
-1.12(-0.63%)
Real-time Data·
ASND Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
ASND is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
173.78177.18
52 wk Range
111.09183.00
Key Statistics
Edit
Prev. Close
176.49
Open
176.42
Day's Range
173.78-177.18
52 wk Range
111.09-183
Volume
276.18K
Average Vol. (3m)
478.75K
1-Year Change
28.51%
Book Value / Share
-3.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASND Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
234.49
Upside
+33.71%
Members' Sentiments
Bearish
Bullish
ProTips
Operates with a moderate level of debt

Ascendis Pharma AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Ascendis Pharma AS Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma AS SWOT Analysis


Analyst Optimism
Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25.
Financial Trajectory
Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026.
Market Dominance
Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients.
Pipeline Promise
Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development.
Read full SWOT analysis

Ascendis Pharma AS Earnings Call Summary for Q4/2024

  • Q4 revenue soars to €173.9M, full-year revenue reaches €363.6M; stock surges 10.2% in aftermarket trading
  • Skytrofa captures 45% of long-acting growth hormone market; UroPath launches with 908 unique patient prescriptions
  • Company aims for cash breakeven by end of 2025; projects potential blockbuster status for multiple product lines
  • R&D costs down 13% YoY; SG&A expenses up to €80.2M from €64M in Q4 2023; €560M cash on hand at year-end
  • CEO hails 2024 as pivotal year; CFO expects UroPath to become multibillion-dollar product and standard of care
Last Updated: 02/12/2025, 05:47 PM
Read Full Transcript

Compare ASND to Peers and Sector

Metrics to compare
ASND
Peers
Sector
Relationship
P/E Ratio
−26.7x−2.1x−0.5x
PEG Ratio
−0.780.040.00
Price / Book
−48.0x1.6x2.6x
Price / LTM Sales
24.7x6.9x3.1x
Upside (Analyst Target)
26.8%136.7%45.7%
Fair Value Upside
Unlock12.2%5.7%Unlock

Analyst Ratings

16 Buy
0 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 234.49
(+33.71% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-1.58 / -1.47
Revenue / Forecast
100.95M / 93.49M
EPS Revisions
Last 90 days

ASND Income Statement

People Also Watch

127.45
CRWV
-7.84%
317.33
ALNY
-1.65%
160.93
CAH
-0.77%
56.34
OKLO
+1.61%
15.243
QBTS
-4.79%

FAQ

What Is the Ascendis Pharma AS (ASND) Stock Price Today?

The Ascendis Pharma AS stock price today is 175.37

What Stock Exchange Does Ascendis Pharma AS Trade On?

Ascendis Pharma AS is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Ascendis Pharma AS?

The stock symbol for Ascendis Pharma AS is "ASND."

What Is the Ascendis Pharma AS Market Cap?

As of today, Ascendis Pharma AS market cap is 10.69B.

What Is Ascendis Pharma AS's Earnings Per Share (TTM)?

The Ascendis Pharma AS EPS (TTM) is -5.82.

When Is the Next Ascendis Pharma AS Earnings Date?

Ascendis Pharma AS will release its next earnings report on Sep 09, 2025.

From a Technical Analysis Perspective, Is ASND a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Ascendis Pharma AS Stock Split?

Ascendis Pharma AS has split 0 times.

How Many Employees Does Ascendis Pharma AS Have?

Ascendis Pharma AS has 1017 employees.

What is the current trading status of Ascendis Pharma AS (ASND)?

As of Jul 11, 2025, Ascendis Pharma AS (ASND) is trading at a price of 175.37, with a previous close of 176.49. The stock has fluctuated within a day range of 173.78 to 177.18, while its 52-week range spans from 111.09 to 183.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.